DocDollars

Jazz Pharmaceuticals Inc.

CA · United States · Reporting entity ID 100000005637

Total reported 2019–2025
$293.8M
#47 of 2,960 reporting companies — 0.4% of all reported industry payments
$49.2M in general payments across 225,703 records, plus $244.6M in research funding across 27,804 records.

How it breaks down

General payments $49,231,614
Research funding $244,602,034

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Jazz Pharmaceuticals Inc. reported $293.8M to US doctors and teaching hospitals from 2019 to 2025, ranking #47 of 2,960 reporting companies. 83% of that was research funding and 17% general payments such as consulting, speaking, food and travel. 225,703 general payment records and 27,804 research records were filed.

Common questions about Jazz Pharmaceuticals Inc.

How much has Jazz Pharmaceuticals Inc. paid US doctors?

Jazz Pharmaceuticals Inc. reported $293,833,648 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $49,231,614 in general payments, $244,602,034 in research funding.

How does Jazz Pharmaceuticals Inc. rank among drug and device companies?

It ranks #47 of 2,960 reporting entities by total reported value, about 0.4% of all industry payments in the dataset.

Does a payment from Jazz Pharmaceuticals Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.